Publications by authors named "Grace Goodhart"

Article Synopsis
  • Mosquito-borne diseases are responsible for over one million deaths annually, highlighting the urgent need for effective control measures to reduce interactions between mosquitoes and their hosts.
  • The study investigates how different sugar diets affect humidity preference and survival rates in specific mosquito species, revealing that the impact varies between species.
  • Notably, the sugar arabinose was found to significantly lower mosquito survival rates, suggesting that targeted sugar treatments could help control mosquito populations and decrease disease transmission.
View Article and Find Full Text PDF

Unlabelled: Humidity levels, like light and temperature, fluctuate daily yet are less predictable; however, whether humidity entrains circadian clocks and enables animals to synchronize behaviors to environmental variations remains unknown. Here, we investigate the circadian humidity entrainment in various insects. Multiple species robustly respond to humidity cycles, and when the humidity cue is removed, their rhythmic behaviors continue, suggesting that humidity-associated rhythmic activities are under circadian control.

View Article and Find Full Text PDF

Despite significant advancements in the treatment of other cancers, pancreatic ductal adenocarcinoma (PDAC) remains one of the world's deadliest cancers. More than 90% of PDAC patients harbor a Kirsten rat sarcoma (KRAS) gene mutation. Although the clinical potential of anti-KRAS therapies has long been realized, all initial efforts to target KRAS were unsuccessful.

View Article and Find Full Text PDF

RAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 61. Small molecule inhibitors of the KRAS(G12C) oncoprotein have demonstrated clinical efficacy in patients with multiple cancer types and have led to regulatory approvals for the treatment of non-small cell lung cancer. Nevertheless, KRAS mutations account for only around 15% of KRAS-mutated cancers, and there are no approved KRAS inhibitors for the majority of patients with tumours containing other common KRAS mutations.

View Article and Find Full Text PDF